PureTech Health plc American Depositary Shares - PRTC STOCK NEWS

Gelesis Holdings (NYSE: GLS) has launched the "Who Said?" marketing campaign for Plenity, aiming to challenge cultural norms around weight loss. This campaign targets the 70% of Americans struggling with excess weight and promotes a new approach to weight management without deprivation. Plenity is FDA-cleared and uses a biomimetic method to enhance satiety, resulting in an average weight loss of 22 pounds in clinical trials. Gelesis anticipates $58 million in revenue for 2022 during its first full year post-launch.

Follica, a biotechnology company, presented survey data on androgenetic alopecia (AGA) treatment at the 2022 Winter Clinical Dermatology Conference. The survey of 303 male participants aged 18-49 revealed significant dissatisfaction with existing AGA treatments, with 64% noting a negative impact on their lives. An overwhelming 74% expressed interest in a novel investigational in-office treatment. The findings underscore the unmet needs in AGA therapies and the potential market for Follica's innovative approach, expected to advance through upcoming clinical trials.

PureTech Health's Founded Entity, Gelesis, has completed a business combination with Capstar Special Purpose Acquisition Corp. Gelesis will begin trading on the New York Stock Exchange under the ticker symbol 'GLS' on January 14, 2022, after securing approximately $105 million in gross proceeds. These funds will primarily support the national launch of Plenity, an FDA-cleared weight management product. With 71 million Americans having gained weight during the pandemic, Gelesis aims to address the rising demand for effective weight management solutions.

PureTech Health plc, a clinical-stage biotherapeutics company, announced that Daphne Zohar, the CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30am EST. The company focuses on developing innovative medicines for severe diseases, including inflammatory and neuropsychological disorders. PureTech has a robust pipeline of 25 therapeutic candidates, with two receiving FDA and European marketing approvals. A webcast of the presentation will be available on their investor site.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced plans to initiate registration-enabling studies for LYT-100, targeting idiopathic pulmonary fibrosis (IPF) through a 505(b)(2) pathway. This includes a dose-ranging study and a Phase 3 study. Recent results show that LYT-100 led to a 50% reduction in gastrointestinal adverse events compared to pirfenidone, the current standard treatment. Additionally, Dr. Paul Ford joins as SVP of Clinical Development to lead LYT-100's advancement, emphasizing the potential for improved tolerability and treatment adherence for IPF patients.

PureTech Health reported significant advancements in its clinical-stage therapeutic candidates across various indications. Key highlights include the progress of LYT-100 in Phase 2 trials for conditions related to inflammation and fibrosis, and the initiation of Phase 1 trials for LYT-200 and LYT-300. The company also noted successful scaling and launch preparations for its Founded Entities, including Gelesis’ Plenity®. The upcoming year is expected to be catalyst-rich with multiple study results promising to impact serious diseases. PureTech continues its commitment to innovative medicine, enhancing shareholder value.

PureTech Health plc presented preclinical proof-of-concept data for LYT-300 at the 60th American College of Neuropsychopharmacology Annual Meeting. LYT-300, an oral allopregnanolone, aims to treat neurological disorders such as depression and anxiety. The data show systemic exposure achieved after oral administration, enhancing the therapeutic potential of the Glyph™ technology platform. LYT-300 has advanced into a Phase 1 clinical study to assess safety and tolerability, with results expected in the second half of 2022.

PureTech Health plc has initiated a Phase 1 clinical study of LYT-300, an oral therapeutic candidate aimed at treating various neurological and neuropsychological conditions such as depression and anxiety. Leveraging the Glyph technology platform, LYT-300 is designed to enhance oral bioavailability compared to natural allopregnanolone, which suffers from poor absorption. The study will assess safety, tolerability, and pharmacokinetics, with results expected in the second half of 2022, potentially guiding future trials for broader indications.

PureTech Health announces the launch of Plenity, an FDA-cleared weight management aid, now available across the United States. The company also appointed Joy Bauer as Chief Nutrition Officer, who will provide nutrition counseling and education for Plenity members. Plenity is designed to help individuals manage weight by feeling satisfied with smaller portions. A subscription costs $98 for a four-week supply. This initiative aims to enhance healthcare access and support sustainable weight management.